Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.92% | -32.98% | 30.14% | 29.32% | 32.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.92% | -32.98% | 30.14% | 29.32% | 32.00% |
| Cost of Revenue | 51.87% | 66.86% | 54.63% | 42.51% | 26.72% |
| Gross Profit | -56.75% | -91.64% | -59.09% | -44.88% | -25.74% |
| SG&A Expenses | 3.88% | 65.95% | 74.27% | 67.10% | 60.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.97% | 66.60% | 60.09% | 49.50% | 36.28% |
| Operating Income | -37.09% | -83.02% | -63.84% | -51.97% | -36.83% |
| Income Before Tax | -38.75% | -86.89% | -70.69% | -60.27% | -39.94% |
| Income Tax Expenses | 88.03% | 97.15% | 100.30% | 89.53% | 72.23% |
| Earnings from Continuing Operations | -39.06% | -89.42% | -73.14% | -62.31% | -41.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.06% | -89.42% | -73.14% | -62.31% | -41.33% |
| EBIT | -37.09% | -83.02% | -63.84% | -51.97% | -36.83% |
| EBITDA | -29.48% | -77.45% | -60.62% | -50.31% | -35.87% |
| EPS Basic | 10.74% | -17.10% | -8.88% | -9.78% | -5.65% |
| Normalized Basic EPS | 10.01% | -15.00% | -6.97% | -8.11% | -4.79% |
| EPS Diluted | 10.74% | -17.10% | -8.88% | -9.78% | -5.65% |
| Normalized Diluted EPS | 10.01% | -15.00% | -6.97% | -8.11% | -4.79% |
| Average Basic Shares Outstanding | 63.55% | 62.93% | 57.12% | 44.42% | 32.07% |
| Average Diluted Shares Outstanding | 63.55% | 62.93% | 57.12% | 44.42% | 32.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |